Esophageal Carcinoma
AQ4N well tolerated in first phase I report
Published in Cancer Weekly, July 6th, 2004
The results were published in the Proceedings of the 2004 American Society for Clinical Oncology (ASCO) Annual Meeting. Novacea has licensed from KuDOS the North American rights to develop and commercialize AQ4N and plans to initiate its clinical development program shortly. KuDOS is developing AQ4N in Europe and other markets outside North America.
The aim of this study is to evaluate the safety and tolerability of AQ4N, a hypoxic-cell activated antitumor therapy, in patients with advanced esophageal carcinoma...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2004-07-06)
More Articles from Cancer Weekly
- Antioxidants
Ascorbic acid makes cancer cells insensitive to chemotherapy - Chemotherapy
Cell density affects the cytotoxicity of daunorubicin and cytosine arabinoside - Hematology
Hematopoietic growth factors manage the effects of non-Hodgkin lymphoma therapy - Oncology
Thrombospondin 1 bears fragments that counteract its antiangiogenic potential - Radiotherapy
HIM-prostate brachytherapy performs well in the community setting - Abdominal Surgery
Surgical interdisciplinarity is needed for abdominal surgery - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
